Tradestie Institutional Equity Comparison Engine

ORKA vs MANE โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ORKA Overall Edge

ORKA Captures Institutional Edge (3โ€“0 Pillars ยท 8โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Oruka Therapeutics, Inc. Common Stock (ORKA) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ORKA trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus MANE at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, ORKA sits in BREAKOUT (19th %ile IV; Dealer Gamma Walls on Pro) against MANE sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ORKA N/M vs MANE N/M Fwd P/E
Growth & Margin Winner ORKA
Op Margin 0.0% vs N/A ยท YoY +0.0% vs N/A
Momentum & Technical Winner ORKA
1Y +278.4% vs +239.2% ยท 52W Pos 83% vs 77%
Options & Structure Winner ORKA
BREAKOUT (19th %ile IV) vs UNCLASSIFIED (N/A IV)
ORKA NASDAQ
Oruka Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.83
-5.23% 1D
Market Cap $7.1B
1M Return +38.79%
1Y Return +278.45%
Forward P/E N/M
Unified AI Score
43.3 / 100 HOLD
Tech 24.0 Fund 40.0 Flow 69.0 Mom 50.0
MANE US Equity
MANE
Institutional Equity
$128.03
-1.26% 1D
Market Cap N/A
1M Return +17.65%
1Y Return +239.15%
Forward P/E N/M
Unified AI Score
38.1 / 100 SELL
Tech 15.0 Fund 36.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ORKA +278.45% MANE +239.15% Spread: +36.62 pp (MANE Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ORKA TTM Op. Margin: 0.0% MANE TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ORKA vs MANE. Trailing 12-month operating profitability (ORKA 0.0% vs MANE N/A) and valuation multiples (ORKA N/M vs MANE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ORKA (8) vs MANE (0)
Institutional Metric ORKA MANE Criterion Row Winner
Market Capitalization Scale $7.1B N/A Larger Scale ORKA
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% N/A Higher Growth ORKA
Operating Margin (TTM) Profitability 0.0% N/A Higher Margin ORKA
Net Profit Margin Profitability 0.0% N/A Higher Margin ORKA
Return on Equity (ROE) Capital Efficiency -18.1% N/A Higher ROE ORKA
52-Week Range Position Momentum 83% ($25โ€“$116) 77% ($32โ€“$157) Stronger Trend ORKA
Beta / 30D Volatility Risk Regime 1.35ฮฒ ยท 68% Vol 1.28ฮฒ ยท 80% Vol Lower Realized Risk ORKA
Unified Institutional Score Composite Signal 43.3 / 100 (HOLD) 38.1 / 100 (SELL) Higher Composite ORKA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ORKA vs MANE Buy Guide
ORKA BREAKOUT
141d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 19th %ile
IV Regime Compressed (<25th %ile)
Live ORKA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MANE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live MANE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ORKA nor MANE registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.